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Cardiac amyloidosis (CA) is characterized by extracellular deposition of protein-derived fibrils and lead to heart 
failure. Gold standard for its etiological diagnosis is endomyocardial biopsy and laboratory tests, both high-cost 
and invasive procedures. Technetium- 99m hydroxymethylene diphosphonate (99mTc-HMDP) scintigraphy is 
important tool for defining CA, specifically transthyretin subtype (ATTR). From July 2020 to February 2021, we 
retrospectively analyzed 18 pts [14 males, 4 females; aged 32-86y] with suspected ATTR, underwent to scintigraphy 
150 min after iv administration of 740 MBq 99mTc-HMDP.Myocardial uptake was assessed optically based on 
Perugini Score (0- 3). Biopsy confirmed diagnosis. Intense (Score 3) and moderate (Score 2) myocardial uptake 
verified in 8 patients by 99mTc-HDMP scintigraphy, was consistent with ATTR suspect. In 10 patient’s cardiac 
radiotracer uptake was absent (Score 0) avoiding biopsy. Our data indicate a 99mTc-HDMP scintigraphy key role 
in the early diagnosis but even more in the exclusion of patients with ATTR subtype, optimizing the management 
of pts who do not require high costs and invasive procedures. 
 






Systemic amyloidosis is heterogeneous disease 
characterized by extracellular deposition of pro-
tein-derived fibrils, namely amyloid, in different 
tissue and organs, including the heart. 
Although considered a rare disease, recent data 
suggest that cardiac amyloidosis is underappreci-
ated as a cause of common cardiac diseases or 
syndromes (Maleszewski 2015). 
While more than 30 proteins are known to be 
capable of aggregating as amyloid in vivo, only 
nine amyloidogenic proteins accumulate in the 
myocardium to cause significant cardiac disease, 
like heart failure, conduction disorders, atrial fi-
brillation and ventricular arrhythmias. 
Two types of amyloid commonly infiltrate the 
heart: immunoglobulin light-chain (AL) amyloid 
and transthyretin (ATTR) amyloid, either in its 
hereditary (ATTRv) or acquired (ATTRwt) 
form. 
Cardiac amyloidosis is diagnosed when amyloid 
fibrils are found within cardiac tissue. (Benson et 
al. 2018). 
 Both invasive and non-invasive diagnostic crite-
ria have been proposed.  
Imaging with cardiac US/MRI provides nonspe-
cific findings. 
Gold standard for etiological diagnosis of car-
diac amyloidosis is endomyocardial biopsy com-
bined with immunohistochemical parame-
ters/mass spectroscopy, both high-cost and in-
vasive procedures.  
Technetium- 99m hydroxymethylene diphos-
phonate (99mTc-HMDP) scintigraphy is a im-
portant tool for defining CA, specifically trans-
thyretin subtype (ATTR). (Ruberg et al. 2019) 
Our work underlines the role of nuclear medi-
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2. Subjects and methods 
 
2.1 Patients’ population 
We retrospectively analyzed eighteen patients 
[14 males, 4 females; aged 32-86y] who were ad-
mitted to our Unit from July 2020 to February 
2021 with suspected CA. 
The following variables were recorded for each 
patient: age, gender, hospitalization department, 
risk factors, symptoms, and previous clinical and 
instrumental evaluation. 
CA suspicion was based on presence clinical car-
diac and extracardiac sign and symptoms, like 
hypotension, macroglossia, skin bruises, carpal 
tunnel syndrome, polyneuropathy and dysauto-
nomia, altered ECG results and laboratory tests, 
pathological instrumental imaging results (Echo-
cardiogram and/ or cardiac magnetic resonance)  
For each patient, an individual informed consen-
sus was obtained allowing us to use all data for 
research purposes. 
 
2.2 Diagnostic exams 
 
Myocardial scintigraphy was acquired using 
gamma OPTIMA NM/CT 670 (GE Medical 
System, West Milwaukee, WI, USA) 150 minutes 
after iv administration of 740 MBq 99mTc- la-
belled hydroxymethylene diphosphonate 
(HMDP). 
Whole -body planar images were acquired 3 
hours after injection. Images were acquired with 
low-energy and high-resolution collimators and 
a scan speed of 10 cm/min. 
Myocardial radiotracer uptake was assessed op-
tically based on Perugini Score (Perugini et al. 
2005): 
0: absent of tracer myocardial uptake and normal 
bone uptake.  
1: mild cardiac uptake, inferior to bon uptake.  
2: moderate cardiac uptake with attenuated 
bone.   
3: high cardiac uptake with decreased or absent 
bone uptake.  (Figure 1) ECG test showed 
low/decreased QRS voltage to degree of LV 
thickness and/or atrio-ventricular conduction 
disease. 
Persistent troponin elevation, disproportionally 
elevated NT-proBNP to degree of heart failure 
and proteinuria (even mild) in laboratory tests 
were also signs that could evoke CA. 
All patients were performed Echocardiogram, 
characterized by presence of granular sparkling 
of myocardium, increased right ventricular wall/ 
valve thickness and pericardial effusion. 
8/18 patients underwent cardiac magnetic reso-
nance that showed subendocardial late gadolin-
ium enhancement, elevated native T1 values, In-










Diffuse intense myocardial uptake (score 3) ver-
ified in 5 patients by 99mTc-HDMP scintigra-
phy. This result, associated with positive hema-
tologic tests (serum free light chains and serum 
and urine immunofixation), was consistent with 
ATTR diagnosis, without biopsy. 
In 3 patients whole-body scintigraphy showed a 
moderate cardiac uptake (Score 2), biopsy was 
necessary to confirm.  
In ten patient’s cardiac radiotracer uptake was 
absent (Score 0) and hematologic tests were neg-
ative, so biopsy invasive procedure was avoiding, 































Figure 11. a) CD117 in tubular structures (luminal) b) c) d) 
S100, nerve trunks permeated by neoplastic proliferation 
 














Cardiac amyloidosis is confirmed when an endo-
myocardial biopsy demonstrates amyloid depos-
its after Congo red staining irrespective of the 
degree of left ventricular (LV) wall thickness. 
Identification of amyloid should be followed by 
classification of the amyloid fibril protein (Gon-
zalez-Lopez et al. 2015). 
Although the gold standard for defining the type 
of amyloid remains mass spectrometry, im-
munohistochemistry, or immunoelectron mi-
croscopy are routinely employed for amyloid 
typing in specialized centers (Maleszewski 2015) 
Diagnosis is also confirmed if amyloid deposits 
within an extracardiac biopsy are accompanied 
either by characteristic features of cardiac amy-
loidosis by echocardiography, in the absence of 
an alternative cause for increased LV wall thick-
ness, or by characteristic features on cardiac 

































99mTc-HDMP scintigraphy important role in 
diagnostic algorithm for cardiac amyloidosis: it's 
a simple, non-invasive, low-cost and widely 
available modality. It does not require prepara-
tion and has no side effect so it can be performed 
in all types of patients including hemodynami-
cally complicated patients (Bokhari er al. 2013).  
The availability of modern SPET/CT technol-
ogy, as in our center, allows to obtain acquisition 
of tomographic images associated with mor-
phology, thus increasing diagnostic accuracy of 
CA. 
Detection of ATTR in our study population by 
99mTc-HDMP scintigraphy was accomplished 
with 100% sensitivity and specificity (Castano et 
al. 2016). 
A diagnostic algorithm based initially on the use 
of bone scintigraphy coupled to assessment for 
monoclonal proteins allows appropriate diagno-
sis in patients with suggestive signs/symptoms. 
Early CA diagnosis, especially in ATTR, is nec-
essary to establish correct therapy.  
Infact, management of cardiac amyloidosis in-
volves treatment and prevention of complica-
tions, and halting or delaying amyloid deposition 
 
Figure 2 Diagnostic algorithm for cardiac amyloidosis. AL, light-chain amyloidosis;ATTR, transthyretin amyloidosis; ATTRv, hereditary 
transthyretin amyloidosis; ATTRwt, wild-type transthyretin amyloidosis; CMR, cardiac magnetic resonance; ECG, electrocardiogram; 
SPECT, single photon emission computed tomography; TTR, transthyretin. 
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by specific treatments, including stabilizing mol-
ecules (tafamidis) and genetic silencers (patisiran 
and inotersen) for ATTR amyloidosis. (Rapezzi 




Our data indicate that 99mTc-HDMP scintigra-
phy has a key role in CA early diagnosis but even 
more in the exclusion of patients with the ATTR 
subtype. 
99mTc-HDMP scintigraphy confirms to be a 
simple, non-invasive, low-cost and widely avail-
able modality. It does not require preparation 
and has no side effect so it can be performed in 
all types of patients including hemodynamically 
complicated patients.  
This examination, optimizing the management 
of pts who do not require admission to proce-
dures with high costs and more invasive, is use-
ful for earlier diagnosis and screening of CA. 
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